Deciphera Pharmaceuticals Inc (NASDAQ:DCPH) – Research analysts at Cantor Fitzgerald lowered their FY2019 earnings per share estimates for shares of Deciphera Pharmaceuticals in a note issued to investors on Tuesday, November 5th. Cantor Fitzgerald analyst C. Duncan now expects that the company will earn ($4.36) per share for the year, down from their previous estimate of ($3.87). Cantor Fitzgerald currently has a “Overweight” rating and a $55.00 price objective on the stock. Cantor Fitzgerald also issued estimates for Deciphera Pharmaceuticals’ FY2020 earnings at ($4.68) EPS.
Several other brokerages also recently commented on DCPH. Leerink Swann raised Deciphera Pharmaceuticals from an “underperform” rating to a “market perform” rating in a research report on Tuesday, October 29th. Piper Jaffray Companies set a $55.00 price objective on Deciphera Pharmaceuticals and gave the company a “buy” rating in a research report on Monday, September 30th. BidaskClub raised Deciphera Pharmaceuticals from a “hold” rating to a “buy” rating in a research report on Tuesday. Svb Leerink raised Deciphera Pharmaceuticals from an “underperform” rating to a “market perform” rating and upped their price objective for the company from $29.00 to $34.00 in a research report on Tuesday, October 29th. Finally, ValuEngine cut Deciphera Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Saturday, October 19th. One investment analyst has rated the stock with a sell rating, four have issued a hold rating and ten have issued a buy rating to the stock. Deciphera Pharmaceuticals presently has a consensus rating of “Buy” and an average target price of $49.31.
Shares of DCPH traded up $0.34 during mid-day trading on Friday, hitting $47.48. 19,022 shares of the stock were exchanged, compared to its average volume of 472,521. The company has a market cap of $2.36 billion, a PE ratio of -16.97 and a beta of 1.96. The firm has a 50-day moving average of $36.53 and a two-hundred day moving average of $28.81. Deciphera Pharmaceuticals has a 52-week low of $19.06 and a 52-week high of $47.99.
Deciphera Pharmaceuticals (NASDAQ:DCPH) last issued its quarterly earnings data on Monday, November 4th. The company reported ($1.28) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($1.19) by ($0.09).
In related news, Director Michael Douglas Taylor sold 22,500 shares of the company’s stock in a transaction on Tuesday, August 13th. The stock was sold at an average price of $40.77, for a total transaction of $917,325.00. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, insider Daniel C. Martin sold 3,000 shares of the company’s stock in a transaction on Thursday, September 19th. The stock was sold at an average price of $35.56, for a total value of $106,680.00. Insiders sold a total of 634,677 shares of company stock valued at $24,390,512 over the last quarter. Company insiders own 7.02% of the company’s stock.
Several hedge funds and other institutional investors have recently modified their holdings of the stock. Alps Advisors Inc. lifted its stake in shares of Deciphera Pharmaceuticals by 22.4% during the 3rd quarter. Alps Advisors Inc. now owns 97,809 shares of the company’s stock worth $3,320,000 after purchasing an additional 17,884 shares during the last quarter. California Public Employees Retirement System acquired a new stake in Deciphera Pharmaceuticals during the third quarter worth about $294,000. Granite Point Capital Management L.P. acquired a new stake in Deciphera Pharmaceuticals during the third quarter worth about $1,425,000. Rhumbline Advisers grew its holdings in Deciphera Pharmaceuticals by 38.4% during the third quarter. Rhumbline Advisers now owns 22,493 shares of the company’s stock worth $763,000 after acquiring an additional 6,245 shares during the period. Finally, Strs Ohio grew its holdings in Deciphera Pharmaceuticals by 82.1% during the third quarter. Strs Ohio now owns 19,300 shares of the company’s stock worth $655,000 after acquiring an additional 8,700 shares during the period. Hedge funds and other institutional investors own 45.71% of the company’s stock.
About Deciphera Pharmaceuticals
Deciphera Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops drugs to enhance the lives of cancer patients by addressing key mechanisms of drug resistance that limit the rate and durability of response of various cancer therapies. The company's lead drug candidate is DCC-2618, which is in Phase III trial for the treatment of gastrointestinal stromal tumors; and that is in Phase I trial for treating advanced systemic mastocytosis, gliomas, melanoma, NSCLC/germ cell/penile, and soft tissue sarcomas.
See Also: What is the Dividend Aristocrat Index?
Receive News & Ratings for Deciphera Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Deciphera Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.